论文部分内容阅读
本刊曾多次收到读者来信,要求增加新药消息,经研究后,本刊拟陆续报导国内外新药在我国医药市场上的动态、新药鉴定、生产和供应情况,以供读者参考选用。 1.第1代头孢菌素 近10年来头孢菌素类(cephalosporins)药物在我国医药市场发展缓慢,与国外差距也大。在日本、西德、欧美等先进国家,第3代头孢菌素已普遍用于临床。在70年代中期,我国第一代头孢菌素、噻孢霉素(cephalothin)方才生产,接着又生产头孢力新(cephalexin),到目前为止第2代和第3代国产头孢菌素已陆续在上海、四川等地试制成功。目前市场上除头孢菌素Ⅰ和头孢菌素Ⅳ以外,其余的头孢菌素都是进口。
This journal has received many letters from readers, asking for news of new drugs. After research, this journal intends to report the dynamics of new drugs at home and abroad, and the identification, production and supply of new drugs for readers’ reference. 1. The first generation cephalosporins cephalosporins in the past 10 years the development of the pharmaceutical market in China is slow, and the gap between foreign large. In Japan, West Germany, Europe and the United States and other advanced countries, the third generation cephalosporins have been widely used in clinical practice. In the mid-1970s, China’s first-generation cephalosporin and cephalothin were only produced and cephlexin was produced. So far, the second and third generation domestic cephalosporins have been successively Shanghai, Sichuan trial success. In addition to the cephalosporin I and cephalosporin IV on the market, the remaining cephalosporins are imported.